Inclusion Criteria

Inclusion:

- Age > 18 and ≤ 85 years

- Histologically confirmed prostate cancer

- Currently receiving LHRH-agonist therapy for greater than 6 months with measurable
fatigue, defined as a score of >1 on the Bruera global fatigue severity scale OR

- Deemed eligible to commence LHRH-agonist therapy, with confirmation of fatigue at
Screening Visit 2

- Have a serum PSA which is stable or decreasing based on the PSA trend over the last 2
values taken at least 2 months apart, with the more recent value taken at least 2
months after initiation of LHRH-agonist therapy.

- Have adequate liver and renal function (Bilirubin ≤ 1.5 x ULN and AST, ALT and Serum
Creatinine < 2 x ULN)

- Able to swallow and retain oral medication

- Life expectancy of at least 1 year

- Able to read and write in English (and therefore accurately complete the required
study questionnaires), understand instructions related to study procedures and give
written informed consent.

Exclusion:

- Current malignancy or received treatment for a previous malignancy within the last 3
years other than prostate cancer (other exceptions are superficial bladder cancer or
non-melanoma skin cancer)

- Previous chemotherapy within the last 5 years

- Anemia (Hemoglobin < 100 g/L)

- Myocardial infarction within past 6 months

- Any unstable serious co-existing medical condition(s) including but not limited to ;
unstable or poorly controlled coronary artery disease, chronic atrial fibrillation,
uncontrolled hypertension, uncontrolled diabetes, Severe bleeding diseases or immune
disorders

- Severe depression as defined by CES-D score >27

- History of motor tics, seizures or a family history of Tourette's syndrome

- Infection with HIV (Human Immunodeficiency Virus), HBV (Hepatitis B) or HCV
(Hepatitis C)

- Evidence of drug or alcohol abuse

- Known hypersensitivity to methylphenidate

- Possess any other contraindications to methylphenidate use